Voters Split on ‘War on Drugs’ Program D.A.R.E.

Attorney General Jeff Sessions’ recent promotion of Drug Abuse Resistance Education unearthed arguments over the efficacy of the hallmark anti-drug program that began proliferating in K-12 schools over three decades ago.

“I believe that D.A.R.E. was instrumental to our success by educating children on the dangers of drug use,” Sessions said during his July 11 remarks at a D.A.R.E. training conference in Dallas, Texas.

“Whenever I ask adults around age 30 about prevention, they always mention the D.A.R.E. program,” he added.

Voters are split over the merits of the program, part of the broader “War on Drugs” made famous in the 1980s by then-first lady Nancy Reagan’s “Just Say No” campaign. A recent Morning Consult/POLITICO survey shows 38 percent of registered voters said D.A.R.E. has been effective, while 35 percent disagreed. Twenty-seven percent said they didn’t know or had no opinion.

The survey shows there is some data to back up Sessions’ anecdote, even though respondents were generally lukewarm on D.A.R.E.’s success. Voters aged 30-44 were the most likely of any age group to have a positive view of D.A.R.E., with 45 percent of those voters backing the program and 34 percent calling it ineffective. By contrast, 33 percent of voters aged 55-64 said D.A.R.E. was effective and 40 percent said it wasn’t. Support for the program was even lower among voters aged 65 and older: Twenty-six percent of those voters said it was effective and 34 percent said it wasn’t.

Younger voters were the most likely to take a position on the program. Only 22 percent of voters aged 18-29 and 21 percent of voters aged 30-44 said they didn’t know or had no opinion, numbers which continued to rise among voters in older age groups, peaking at 39 percent among voters 65 and older. The youngest voters (aged 18-29) were also the most closely split on D.A.R.E.’s value, with 41 percent saying it was an effective program and 37 percent disagreeing.

There was little partisan divide on the topic, although independents (31 percent) were less likely than Democrats (41 percent) or Republicans (40 percent) to back the program.

While the voting public is split on its effectiveness, the experts are not: They firmly argue that the program has been a waste of government resources in combating drug abuse.

“There are multiple studies that have shown that D.A.R.E. has had no meaningful long-term impact on drug abuse of any kind, including on opioid use,” said Jonathan Blanks, a research associate at the libertarian-leaning Cato Institute’s Project on Criminal Justice, in a Thursday phone interview.

A list compiled by the Center for Evidence-Based Crime Policy at George Mason University contains various studies showing D.A.R.E.’s ineffectiveness over the past few decades. One 2009 study even found an increase in self-reported alcohol and cigarette use from D.A.R.E. participants.

Briefings

Health Brief: GOP Senators Ask CBO to Fast-Track ACA Overhaul Review

Senate Republican leaders have asked the Congressional Budget Office to fast-track consideration of a plan from Sens. Lindsey Graham (R-S.C.) and Bill Cassidy (R-La.) to overhaul the Affordable Care Act. The CBO is reportedly in the process of analyzing the cost and coverage impact of the plan, as Republicans face pressure to make one last attempt at undoing the ACA before GOP senators’ ability to pass legislation with a simple majority expires on Sept. 30.

Health Brief: Week in Review & What’s Ahead

HELP Committee Chairman Lamar Alexander (R-Tenn.) hopes to reach a deal with Democrats on a plan to shore up the ACA exchanges early this week. A final agreement, if reached, is likely to extend key insurer payments, known as cost-sharing reductions, and include reforms to make it easier for states to establish reinsurance programs. Some Republicans are also pushing to give states more flexibility over required benefits in Obamacare plans, a proposal that is controversial with Democrats.

Health Brief: Some Moderate House Democrats Seek ACA Stabilization

While progressives this week rallied behind Sen. Bernie Sanders’ (I-Vt.) single-payer health care bill, a group of moderate House Democrats in the New Democrat Coalition aligned themselves with the Senate Health, Education, Labor and Pensions Committee’s bipartisan push to stabilize the Affordable Care Act exchanges, which Committee Chairman Lamar Alexander (R-Tenn.) aims to reach a final deal on by early next week.

Health Brief: Deal Reached to Extend CHIP Funding

Senate Finance Committee leaders reached a deal on a five-year reauthorization of the Children’s Health Insurance Program, in a win for children’s health advocates who are seeking longer-term funding certainty for the program, which will expire at the end of the month without congressional action. The deal also gradually phases out the enhanced federal share of funding for state CHIP programs, which was increased under the Affordable Care Act by 23 percentage points.

Health Brief: Some Navigators Shut Down Ahead of ACA Enrollment Period

Several navigator organizations, including one that received the largest federal grant for Obamacare enrollment activities in 2016, are suspending operations ahead of the 2018 open enrollment season because they haven’t received contracts for funding from the Department of Health and Human Services, which could cause enrollment to plummet. The Trump administration announced plans last month to cut funding for navigator groups by about 40 percent, but health officials haven’t said whether the grants would end altogether.

Health Brief: Teva Names New CEO

H. Lundbeck A/S’s Kaare Schultz was named as Teva Pharmaceutical Industries Ltd.’s new chief executive officer, ending a seven-month search by the world’s largest generic drug maker to find a new leader. Schultz could face pressure to split the company into two businesses, one focusing on patented specialty drugs and the other on cheap copycat medicines

Load More